The effects of a bioavailable curcumin formulation on Alzheimer’s disease pathologies: A potential risk for neuroinflammation

Abstract

Alzheimer’s disease (AD) is a common cause of dementia characterized by the presence of two proteinaceous deposits in the brain. These pathologies may be a consequence of complex interactions between neurons and glia before the onset of cognitive impairments. Curcumin, a bioactive compound found in turmeric, is a promising candidate for AD because it alleviates neuropathologies in mouse models of the disease. Although its clinical efficacy has been hindered by low oral bioavailability, the development of new formulations may overcome this limitation. The purpose of this study was to determine the effects of a bioavailable curcumin formulation in a mouse model of AD. The formulation was administered to mice in drinking water after encapsulation into micelles using a previously validated method. A neuropathological assessment was performed to determine if it slows or alters the course of the disease. Cognitive performance was not included because it had already been assessed by a previous study. The bioavailable curcumin formulation was unable to alter the size or number of amyloid plaques in a transgenic mouse model. In addition, mechanisms that regulate amyloid beta production were unchanged, suggesting that the disease had not been altered. The number of reactive astrocytes in the hippocampus and dentate gyrus was not altered by curcumin. However, protein levels of glial fibrillary acidic protein were increased overall in the brain, suggesting that it may have aggravated neuroinflammation. Therefore, a higher dosage, despite its enhanced oral bioavailability, may have a potential risk for neuroinflammation.

Keywords

Alzheimer's disease / amyloid pathology / curcumin / neurodegeneration

References

[1] Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125.

[2] United Nations. World Population Ageing 2019, United Nations;2022. https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2021/Aug/world_population_ageing_2019_report_3aug.2021.pdf

[3] Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59-70.

[4] Mi Z, Abrahamson EE, Ryu AY, et al. Loss of precuneus dendritic spines immunopositive for spinophilin is related to cognitive impairment in early Alzheimer’s disease. Neurobiol Aging. 2017;55:159-166.

[5] De Strooper B, Karran E. The cellular phase of Alzheimer’s disease. Cell. 2016;164(4):603-615.

[6] Kirouac L, Rajic AJ, Cribbs DH, Padmanabhan J. Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer’s disease. eNeuro. 2017;4(2):ENEURO.0149-16.2017.

[7] Campolo M, Casili G, Lanza M, et al. Multiple mechanisms of dimethyl fumarate in amyloid β-induced neurotoxicity in human neuronal cells. J Cell Mol Med. 2018;22(2):1081-1094.

[8] Saadipour K, Mañucat-Tan NB, Lim Y, et al. p75 neurotrophin receptor interacts with and promotes BACE1 localization in endosomes aggravating amyloidogenesis. J Neurochem. 2018;144(3):302-317.

[9] Shen LL, Li WW, Xu YL, et al. Neurotrophin receptor p75 mediates amyloid β-induced tau pathology. Neurobiol Dis. 2019;132:104567.

[10] Yang T, Tran KC, Zeng AY, Massa SM, Longo FM. Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies. Sci Rep. 2020;10(1):20322.

[11] Kamphuis W, Kooijman L, Orre M, Stassen O, Pekny M, Hol EM. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer’s disease. GLIA. 2015;63(6):1036-1056.

[12] Serrano-Pozo A, Betensky RA, Frosch MP, Hyman BT. Plaque-associated local toxicity increases over the clinical course of Alzheimer disease. Am J Pathol. 2016;186(2):375-384.

[13] Maiti P, Paladugu L, Dunbar GL. Retracted article: solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the 5xFAD mouse model of Alzheimer’s disease. BMC Neurosci. 2018;19(1):7.

[14] Sundaram JR, Poore CP, Sulaimee NHB, et al. Curcumin ameliorates neuroinflammation, neurodegeneration, and memory deficits in p25 transgenic mouse model that bears hallmarks of Alzheimer’s disease. J Alzheimer’s Dis. 2017;60(4):1429-1442.

[15] He Y, Wang P, Wei P, et al. Effects of curcumin on synapses in APPswe/PS1dE9 mice. Int J Immunopathol Pharmacol. 2016;29(2):217-225.

[16] Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid βoligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892-5901.

[17] Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease. J Pharmacol Exp Ther. 2008;326(1):196-208.

[18] Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620-1637.

[19] Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer’s Res Ther. 2012;4(43):43.

[20] Hoppe JB, Coradini K, Frozza RL, et al. Free and nanoencapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt/GSK-3βsignaling pathway. Neurobiol Learn Mem. 2013;106:134-144.

[21] Parikh A, Kathawala K, Song Y, Zhou XF, Garg S. Curcumin-loaded self-nanomicellizing solid dispersion system: part I: development, optimization, characterization, and oral bioavailability. Drug Delivery Transl Res. 2018;8(5):1389-1405.

[22] Tiekou Lorinczova H, Fitzsimons O, Mursaleen L, Renshaw D, Begum G, Zariwala MG. Co-administration of iron and a bioavailable curcumin supplement increases serum BDNF levels in healthy adults. Antioxidants (Basel). 2020;9(8):1-16.

[23] Parikh A, Kathawala K, Li J, et al. Curcumin-loaded self-nanomicellizing solid dispersion system: part II: in vivo safety and efficacy assessment against behavior deficit in Alzheimer disease. Drug Deliv Transl Res. 2018;8(5):1406-1420.

[24] Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γsecretase. Hum Mol Gen. 2004;13(2):159-170.

[25] Yao XQ, Jiao SS, Saadipour K, et al. p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer’s disease. Mol Psychiatry. 2015;20(11):1301-1310.

[26] Wang QH, Wang YR, Zhang T, et al. Intramuscular delivery of p75NTR ectodomain by an AAV vector attenuates cognitive deficits and Alzheimer’s disease-like pathologies in APP/PS1 transgenic mice. J Neurochem. 2016;138(1):163-173.

[27] Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem. 1961;10(3):355-364.

[28] Clement CG, Truong LD. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis. Hum Pathol. 2014;45(8):1766-1772.

[29] Hunter S, Brayne C. Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research? J Negat Results Biomed. 2017;16(1):1-8.

[30] Reyes-Marin KE, Nuñez A. Seizure susceptibility in the APP/PS1 mouse model of Alzheimer’s disease and relationship with amyloid βplaques. Brain Res. 2017;1677:93-100.

[31] Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ:25 years of image analysis. Nat Methods. 2012;9(7):671-675.

[32] Abner EL, Kryscio RJ, Schmitt FA, et al. Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Ann Neurol. 2017;81(4):549-559.

[33] Yakupova EI, Bobyleva LG, Vikhlyantsev IM, Bobylev AG. Congo red and amyloids: history and relationship. Biosci Rep. 2019;39(1):1-22.

[34] Chen J, Zhang T, Jiao S, et al. proBDNF accelerates brain amyloid-βdeposition and learning and memory impairment in APPswePS1dE9 transgenic mice. J Alzheimer’s Dis. 2017;59(3):941-949.

[35] Mañucat-Tan NB, Saadipour K, Wang YJ, Bobrovskaya L, Zhou XF. Cellular trafficking of amyloid precursor protein in amyloidogenesis physiological and pathological significance. Mol Neurobiol. 2019;56(2):812-830.

[36] Kandalepas P, Vassar R. The normal and pathologic roles of the Alzheimer’s β-secretase, BACE1. Curr Alzheimer Res. 2014;11(5):441-449.

[37] Wei H, Zhang H, Wang X, et al. Direct activation of protein phosphatase 2A (PP2A) by tricyclic sulfonamides ameliorates Alzheimer’s disease pathogenesis in cell and animal models. Neurotherapeutics. 2020;17(3):1087-1103.

[38] Zeke A, Misheva M, Reményi A, Bogoyevitch MA. JNK signaling: regulation and functions based on complex protein-protein partnerships. Microbiol Mol Biol Rev. 2016;80(3):793-835.

[39] Toh WH, Chia PZC, Hossain MI, Gleeson PA. GGA1 regulates signal-dependent sorting of BACE1 to recycling endosomes, which moderates Aβproduction. Mol Biol Cell. 2018;29(2):191-208.

[40] Sun M, Zhang H. Par3 and aPKC regulate BACE1 endosome-to-TGN trafficking through PACS1. Neurobiol Aging. 2017;60:129-140.

[41] Eggert S, Thomas C, Kins S, Hermey G. Trafficking in Alzheimer’s disease: modulation of APP transport and processing by the transmembrane proteins LRP1, sorLA, sorCS1c, sortilin, and calsyntenin. Mol Neurobiol. 2018;55(7):5809-5829.

[42] Saadipour K, Yang M, Lim Y, et al. Amyloid beta1–42(Aβ42) up-regulates the expression of sortilin via the p75NTR/RhoA signaling pathway. J Neurochem. 2013;127(2):152-162.

[43] Escartin C, Galea E, Lakatos A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24(3):312-325.

[44] Maiti P, Bowers Z, Bourcier-Schultz A, Morse J, Dunbar GL. Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis. Alzheimers Res Ther. 2021;13(1):1-22.

[45] Shentu YP, Huo Y, Feng XL, et al. CIP2A causes tau/APP phosphorylation, synaptopathy, and memory deficits in Alzheimer’s disease. Cell Rep. 2018;24(3):713-723.

[46] Zhang L, Fang Y, Xu Y, et al. Curcumin improves amyloid beta-peptide (1-42) induced spatial memory deficits through BDNF-ERK signaling pathway. PLoS One. 2015;10(6):1-17.

[47] Chang KA, Kim HS, Ha TY, et al. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol. 2006;26(11):4327-4338.

[48] Song XJ, Zhou HY, Sun YX, Huang HC. Inhibitory effects of curcumin on H₂O₂-induced cell damage and APP expression and processing in SH-SY5Y cells transfected with APP gene with Swedish mutation. Mol Biol Rep. 2020;47(3):2047-2059.

[49] Minett T, Classey J, Matthews FE, et al. Microglial immunophenotype in dementia with Alzheimer’s pathology. J Neuroinflammation. 2016;13(1):135.

[50] Jiwaji Z, Tiwari SS, Avilés-Reyes RX, et al. Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aβpathology. Nat Commun. 2022;13(1):135.

[51] Metaxas A, Thygesen C, Kempf SJ, et al. Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer’s disease. Sci Rep. 2019;9(1):15758.

[52] Feng H, Wang C, He W, et al. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects. Metab Brain Dis. 2019;34(2):583-591.

[53] Chen F, He Y, Wang P, et al. Curcumin can influence synaptic dysfunction in APPswe/PS1dE9 mice. J Tradit Chin Med. 2018;5(2):168-176.

RIGHTS & PERMISSIONS

2024 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.